Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pedro Cahn

Showing results (191-200 of 207) with videos related to

Pageof 21
Sort By:
Journal of the International AIDS Society|March 22, 2016
Health outcomes among HIV-positive Latinos initiating antiretroviral therapy in North America versus Central and South AmericaCarina Cesar, John R Koethe, Mark J Giganti, et al.
The Lancet. HIV|September 19, 2017
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trialPedro Cahn, Richard Kaplan, Paul E Sax, et al.
AIDS (London, England)|September 17, 2021
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infectionPedro Cahn, Juan Sierra Madero, José R Arribas, et al.
Lancet (London, England)|February 28, 2026
Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trialChloe Orkin, Peter J Ruane, Malcolm Hedgcock, et al.
International Journal of Behavioral Medicine|July 30, 2020
Cumulative Burden of Mental Health Factors and Engagement in HIV Care in ArgentinaOmar Sued, Diego Cecchini, John M Abbamonte, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 14, 2019
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical TrialsPedro Cahn, Juan Sierra Madero, José R Arribas, et al.
International Journal of Behavioral Medicine|January 27, 2021
Correction to: Cumulative Burden of Mental Health Factors and Engagement in HIV Care in ArgentinaOmar Sued, Diego Cecchini, John M Abbamonte, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 7, 2004
Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational studyCristina Mussini, Patrizio Pezzotti, José M Miró, et al.
The Lancet. HIV|November 28, 2025
Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trialSusan P Buchbinder, Sabrina Spinosa Guzman, Jorge Sanchez, et al.
Journal of the International AIDS Society|April 7, 2016
A picture is worth a thousand words: maps of HIV indicators to inform research, programs, and policy from NA-ACCORD and CCASAnet clinical cohortsKeri N Althoff, Peter F Rebeiro, David B Hanna, et al.
Pageof 21

Showing results (191-200 of 207) with videos related to

Sort By:
Pageof 21
Journal of the International AIDS Society|March 22, 2016
Health outcomes among HIV-positive Latinos initiating antiretroviral therapy in North America versus Central and South AmericaCarina Cesar, John R Koethe, Mark J Giganti, et al.
The Lancet. HIV|September 19, 2017
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trialPedro Cahn, Richard Kaplan, Paul E Sax, et al.
AIDS (London, England)|September 17, 2021
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infectionPedro Cahn, Juan Sierra Madero, José R Arribas, et al.
Lancet (London, England)|February 28, 2026
Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trialChloe Orkin, Peter J Ruane, Malcolm Hedgcock, et al.
International Journal of Behavioral Medicine|July 30, 2020
Cumulative Burden of Mental Health Factors and Engagement in HIV Care in ArgentinaOmar Sued, Diego Cecchini, John M Abbamonte, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 14, 2019
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical TrialsPedro Cahn, Juan Sierra Madero, José R Arribas, et al.
International Journal of Behavioral Medicine|January 27, 2021
Correction to: Cumulative Burden of Mental Health Factors and Engagement in HIV Care in ArgentinaOmar Sued, Diego Cecchini, John M Abbamonte, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 7, 2004
Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational studyCristina Mussini, Patrizio Pezzotti, José M Miró, et al.
The Lancet. HIV|November 28, 2025
Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trialSusan P Buchbinder, Sabrina Spinosa Guzman, Jorge Sanchez, et al.
Journal of the International AIDS Society|April 7, 2016
A picture is worth a thousand words: maps of HIV indicators to inform research, programs, and policy from NA-ACCORD and CCASAnet clinical cohortsKeri N Althoff, Peter F Rebeiro, David B Hanna, et al.
Pageof 21